ORION CORPORATION: Amendment of Section 12 of Articles of Association entered in the Trade Register

 

 

ORION CORPORATION   STOCK EXCHANGE RELEASE  8 April 2010  AT 9.50 AM EET              

 

 

 

 

The amendment of Section 12 of the Articles of Association of Orion Corporation in accordance with the decision by the AGM held on 24 March 2010 has been entered in the Trade Register. The current Articles of Association are available on the company's website in the address www.orion.fi/articles-of-association. The decisions of the AGM were published in a Stock Exchange Release of 24 March 2010.

 

 

Orion Corporation

 

 

Timo Lappalainen          Olli Huotari

President and CEO       SVP, Corporate Functions

 

 

Contact person:

Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, GSM +358 50 966 3054

 

 

 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi

 

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler^® pulmonary drugs.

 

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.